- Trials with a EudraCT protocol (14)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
14 result(s) found for: Aminoglycosides.
Displaying page 1 of 1.
EudraCT Number: 2008-005110-41 | Sponsor Protocol Number: 9999999999999999999 | Start Date*: 2008-12-09 |
Sponsor Name:not applicable | ||
Full Title: Circadian Influence on Renal Clearance of Aminoglycosides in cystic fibrosis patients | ||
Medical condition: Repeated or extended dosing of aminoglycosides may cause damage to the proximal tubuli, resulting in renal impairment. Renal impairment affects up to 40 % of adult CF patients, measured after estim... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2019-003016-32 | Sponsor Protocol Number: APHP180690 | Start Date*: 2020-01-24 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris | ||
Full Title: Impact of aminoglycosides-based antibiotics combination and protective isolation on outcomes in critically-ill neutropenic patients with sepsis:A randomized 2 by 2 factorial design randomized pragm... | ||
Medical condition: neutropenic patients with sepsis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004440-19 | Sponsor Protocol Number: CLAM320B2202 | Start Date*: 2016-03-01 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A 30-month multicenter, phase 2b/3, randomized, open label trial to evaluate the efficacy and safety of clofazimine administered orally in addition to background regimen compared to background regi... | |||||||||||||
Medical condition: Treatment of multidrug-resistant pulmonary tuberculosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LV (Prematurely Ended) LT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-001840-83 | Sponsor Protocol Number: SAGA | Start Date*: 2022-04-26 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Short-course aminoglycosides as adjunctive treatment in adults with sepsis | ||
Medical condition: Patients admitted with sepsis of unknown origin, suspected urinary origin or suspected abdominal origin | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001576-30 | Sponsor Protocol Number: 15783408 | Start Date*: 2016-11-07 | |||||||||||
Sponsor Name:CHU TOULOUSE | |||||||||||||
Full Title: Interest of Intra-nodal injection of gentamicin for the treatment of suppurated cat scratch disease’s lymphadenitis: a randomized controlled study. "BIGG" : Bartonellosis and intra-nodal injection... | |||||||||||||
Medical condition: Bartonellosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004814-84 | Sponsor Protocol Number: CS/2016/01 | Start Date*: 2016-05-18 |
Sponsor Name:Sint Antonius Hospital | ||
Full Title: Individualized dosing of aminoglycosides, quinolones and glycopeptide antibiotics in (morbidly) obese patients | ||
Medical condition: Morbid obesity | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2010-023030-23 | Sponsor Protocol Number: 10076 | Start Date*: 2010-12-24 |
Sponsor Name:The Univeristy of Nottingham [...] | ||
Full Title: Circadian Rhythm In Tobramycin Elimination in Cystic Fibrosis (CRITIC) - a Randomised Pharmacokinetic Comparison of Tobramycin in CF | ||
Medical condition: Cystic fibrosis | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2013-001048-73 | Sponsor Protocol Number: BAY41-6551/13084 | Start Date*: 2013-07-25 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Pati... | |||||||||||||
Medical condition: Gram-negative pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002531-29 | Sponsor Protocol Number: VIS649-201 | Start Date*: 2020-03-24 | |||||||||||
Sponsor Name:Visterra, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study to Evaluate the Efficacy and Safety of VIS649 in Participants with Immunoglobulin A (IgA) Nephropathy | |||||||||||||
Medical condition: Immunoglobulin A (IgA) Nephropathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-004764-39 | Sponsor Protocol Number: CTBM100C2303E1 | Start Date*: 2009-09-07 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase III Open-Label Extension Study to Assess the Safety and Efficacy of Tobramycin Inhalation Powder after Manufacturing Process Modifications (TIPnew) in Cystic Fibrosis (CF) Subjects Who Comp... | |||||||||||||
Medical condition: Pseudomonas aeruginosa infection in cystic fibrosis patients | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) LV (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-000966-12 | Sponsor Protocol Number: EL-004 | Start Date*: 2019-11-18 | |||||||||||
Sponsor Name:Eloxx Pharmaceuticals Inc | |||||||||||||
Full Title: A Phase 2 Open Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dose Levels of Subcutaneously Administered ELX-02 in Patients with Cystic Fibrosis... | |||||||||||||
Medical condition: Cystic fibrosis (CF) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-000906-35 | Sponsor Protocol Number: BAY41-6551/13085 | Start Date*: 2008-11-28 |
Sponsor Name:Bayer Schering Pharma AG | ||
Full Title: A Prospective, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of BAY 41-6551 as Adjunctive Therapy in Intubated and Mechanically-Ventilated Pati... | ||
Medical condition: Gram-negaive pneumonia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: CZ (Completed) HU (Completed) NL (Completed) BE (Completed) ES (Completed) FR (Completed) LV (Prematurely Ended) GR (Completed) PT (Completed) IT (Prematurely Ended) PL (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-001159-11 | Sponsor Protocol Number: POL7080-010 | Start Date*: 2019-02-08 | |||||||||||
Sponsor Name:Polyphor Ltd. | |||||||||||||
Full Title: A multicenter, open-label, sponsor-blinded, randomized, active-controlled, parallel group, pivotal study to evaluate the efficacy, safety, and tolerability of murepavadin given with ertapenem versu... | |||||||||||||
Medical condition: Nosocomial pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) FR (Prematurely Ended) LT (Prematurely Ended) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-003933-27 | Sponsor Protocol Number: POL7080-011 | Start Date*: 2018-01-29 | |||||||||||
Sponsor Name:Polyphor Ltd. | |||||||||||||
Full Title: A multicenter, open-label, randomized, active-controlled, parallel group, pivotal study to investigate the efficacy, safety and tolerability, and pharmacokinetics of murepavadin combined with one a... | |||||||||||||
Medical condition: Ventilator-associated bacterial pneumonia (VABP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) EE (Prematurely Ended) ES (Prematurely Ended) FR (Prematurely Ended) HR (Completed) GR (Prematurely Ended) RO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
